 | 
 | |
- January 28, 2008 - Nile Therapeutics Appoints Gregory W. Schafer to Board of Directors » Read
- February 5, 2008 - Nile Therapeutics, Inc. to Present at Upcoming BIO CEO & Investor Conference » Read
- February 6, 2008 - Nile Therapeutics Announces Dosing of First Heart Failure Patient in Phase Ib Study of CD-NP » Read
- February 25, 2008 - Hsiao Dee Lieu, M.D., F.A.C.C. Named VP of Clinical Research of Nile Therapeutics » Read
- March 13, 2008 - Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results » Read
- May 8, 2008 - Jane Moffitt, J.D., LL.M. Named Vice President of Regulatory Affairs of Nile Therapeutics » Read
- May 12, 2008 - Nile Therapeutics Announces Move to The NASDAQ Capital Market » Read
- May 13, 2008 - Nile Therapeutics to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference » Read
- May 15, 2008 - Nile Therapeutics Reports 2008 First Quarter Financial Results » Read
- June 18, 2008 - Nile Therapeutics Completes License Agreement for CU-NP, a Rationally Designed Natriuretic Peptide » Read
- July 11, 2008 - Nile Therapeutics Announces Dosing in Phase IIa Study of CD-NP in Heart Failure Patients » Read
- July 16, 2008 - Nile Therapeutics to Ring the NASDAQ Stock Market Closing Bell » Read
- July 30, 2008 - Nile Therapeutics Announces Dosing in Second Phase Ib Study of CD-NP in Heart » Read
- August 14, 2008 - Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results » Read
- August 27, 2008 - Nile Therapeutics to Present at BioCentury's NewsMakers in the Biotech Industry Conference » Read
- October 1, 2008 - Nile Therapeutics to Present at the Maxim Group Growth Conference » Read
- October 14, 2008 - Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure » Read
- November 3, 2008 - Nile Therapeutics to Present at Two Upcoming Investor Conferences » Read
- November 13, 2008 - Nile Therapeutics, Inc. Reports 2008 Third Quarter Financial Results » Read
- December 9, 2008 - Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure » Read
| |
|
